NASDAQ: LSTA - Lisata Therapeutics, Inc.

Rentabilité sur six mois: -12.71%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Lisata Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases.

plus de détails
Its product candidates include LSTA1, which is in Phase 1b/2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; HONEDRA, a recipient of SAKIGAKE designation critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and LSTA201, a CD34+ cell therapy for the treatment of chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 1999-03-01
ISIN US1280583022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lisata.com
Цена ао 3.17
Changement de prix par jour: -3.51% (3.13)
Changement de prix par semaine: +11.44% (2.71)
Changement de prix par mois: +7.1% (2.82)
Changement de prix sur 3 mois: +3.78% (2.91)
Changement de prix sur six mois: -12.71% (3.46)
Changement de prix par an: +10.63% (2.73)
Evolution du prix sur 3 ans: +239.34% (0.89)
Evolution du prix sur 5 ans: +9.82% (2.75)
Evolution des prix sur 10 ans: 0% (3.0201)
Evolution des prix depuis le début de l'année: +3.78% (2.91)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0.1067 10
P/BV 0.477 10
P/E 0 0
EV/EBITDA -0.0219 0
Total: 6.25

Efficacité

Nom Signification Grade
ROA, % -38.1 0
ROE, % -43.28 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.012 10
Total: 9.8

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 727.43 10
Rentabilité Ebitda, % 32.22 5
Rentabilité EPS, % -91.16 0
Total: 3.4
Plus de détails

Établissements Volume Partager, %
Bml Capital Management, LLC 269839 3.25
Vanguard Group Inc 176965 2.13
Renaissance Technologies, LLC 97222 1.17
Blackrock Inc. 56250 0.68
Geode Capital Management, LLC 43390 0.52
Susquehanna International Group, LLP 33749 0.41
State Street Corporation 14348 0.17
Citadel Advisors Llc 14131 0.17
Cook Wealth Management Group LLC 12175 0.15
HighTower Advisors, LLC 10044 0.12



Superviseur Titre d'emploi Paiement Année de naissance
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. President, CEO & Director 1.16M 1957 (68 années)
Dr. Kristen K. Buck M.D. Executive VP of R&D and Chief Medical Officer 938.42k 1974 (51 année)
Mr. James Nisco Senior VP of Finance, Treasurer, CAO & Principal Financial and Accounting Officer N/A 1971 (54 année)
Mr. Tariq Imam Vice President of Business Development & Operations and Corporate Counsel N/A
Mr. Gregory S. Berkin Chief Information Officer N/A
Mr. John D. Menditto Vice President of Investor Relations & Corporate Communications N/A
Ms. Gail Holler Vice President of Human Resources N/A 1959 (66 années)
Dr. William K. Sietsema Ph.D. Vice President of Global Regulatory Affairs 350.55k 1956 (69 années)

Adresse: United States, Basking Ridge. NJ, 110 Allen Road - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.lisata.com